Zorbtive is a drug owned by Emd Serono Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 27, 2016. Details of Zorbtive's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5898030 | hGH containing pharmaceutical compositions |
Apr, 2016
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Zorbtive is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zorbtive's family patents as well as insights into ongoing legal events on those patents.
Zorbtive's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zorbtive's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 27, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zorbtive Generics:
There are no approved generic versions for Zorbtive as of now.
Alternative Brands for Zorbtive
There are several other brand drugs using the same active ingredient (Somatropin Recombinant) as Zorbtive. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Emd Serono |
| |||
| Genentech |
| |||
| Novo Nordisk Inc |
| |||
| Pharmacia And Upjohn |
|
About Zorbtive
Zorbtive is a drug owned by Emd Serono Inc. Zorbtive uses Somatropin Recombinant as an active ingredient. Zorbtive was launched by Emd Serono in 2003.
Approval Date:
Zorbtive was approved by FDA for market use on 01 December, 2003.
Active Ingredient:
Zorbtive uses Somatropin Recombinant as the active ingredient. Check out other Drugs and Companies using Somatropin Recombinant ingredient
Dosage:
Zorbtive is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 8.8MG/VIAL | INJECTABLE | Prescription | INJECTION |